Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology

  title={Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent{\textregistered} Technology},
  author={Takefumi Matsushita},
  journal={The Korean Journal of Hematology},
  pages={148 - 150}
With more than 30 therapeutic antibodies approved worldwide, therapeutic antibodies have become a major category in the pharmaceutical market. In an effort to further expand the potential of therapeutic antibodies, several approaches are being employed, such as improving the effector functions of the antibodies, designing antibody-drug conjugates, and downsizing the antibody molecule. Among these approaches, enhancing antibody-dependent cellular cytotoxicity (ADCC), which is the major effector… 

Figures from this paper

Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering
Significant growth in knowledge of Fc glycosylation over the last decade, combined with advancement in genetic engineering, has empowered glyco-engineering to fine-tune antibody therapeutics.
Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Current antibody engineering strategies for the modification of therapeutic antibodies in the areas of Fc engineering and pH-dependent antigen binding, bispecific antibodies and ADCs are covered.
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
The underpinning structure-function relationships and how the Fc has been engineered to produce an increasing number of antibodies that are appearing in the clinic with augmented abilities to treat cancer are revealed.
Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model
Fucose-depleted trastuzumab is used as a model to show the advantages of this new class of anticancer agents and it is predicted that these advantages will translate clinically into improved therapeutics for many patients including those with HER2-overexpressing neoplasms.
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
The advances in the understanding of Fc glycobiology and development of novel glycoengineering technologies have facilitated the generation of therapeutic mAbs with homogenous glycoforms and improved therapeutic efficacy.
Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells
Live-cell time-lapse microscopy of individual cell-cell interactions in an aqueous environment and a three-dimensional matrix revealed that anti-CD20-AF induced more rapid killing of opsonized target cells, which increased engagement of multiple targets and enabled a greater proportion of NK cells to perform serial killing.


Engineered antibody Fc variants with enhanced effector function.
  • G. Lazar, W. Dang, B. Dahiyat
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
The engineered Fc regions offer a means for improving the next generation of therapeutic antibodies and have the potential to broaden the diversity of antigens that can be targeted for antibody-based tumor therapy.
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
The glycosylation pattern of chCE7 was engineered in Chinese hamster ovary cells with tetracycline–regulated expression of GnTIII to optimize the ADCC activity, and this activity correlated with the level of constant region–associated, bisected complex oligosaccharides determined by matrix–assisted laser desorption/ionization time–of–flight mass spectrometry.
Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma
The results indicate that defucosylated antibodies with enhanced ADCC as well as potent antitumor activity in vivo are promising candidates for the novel antibody-based therapy.
Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL)
A multicenter phase II study of KW-0761 for relapsed patients with CCR4-positive ATL to evaluate its efficacy, pharmacokinetics (PK), safety and immunogenicity found it to be well tolerated and showed encouraging clinical activity.
Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients
KW-0761 is well tolerated at doses of 0.1–1.0 mg/kg and there does not appear to be any dose relationship with the incidence or severity of the AEs, and promising results warrant further clinical studies using KW-761 in refractory or relapsed CTCL patients.
Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity
The results demonstrate that FUT8−/− cells are ideal host cell lines to stably produce completely defucosylated high‐ADCC antibodies with fixed quality and efficacy for therapeutic use.
The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity*
The results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*
Select IgG1 variants with improved binding to FcγRIIIA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/Fcγ RIIIA co-crystal structure.
Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).
It is demonstrated that cell lines and a primary sample of t(17;19)-ALL expressed LMO2 at significantly higher levels than other B-precursor ALLs did and could be a target for a new therapeutic modality for extremely chemo-resistant t( 17; 19)-ALL.